Breaking News Instant updates and real-time market news.

NFLX

Netflix

$362.50

-3.22 (-0.88%)

, EBAY

eBay

$39.03

-0.87 (-2.18%)

09:01
07/18/19
07/18
09:01
07/18/19
09:01

Fly Intel: Pre-market Movers

UP AFTER EARNINGS: Phillip Morris (PM), up 4%... eBay (EBAY), up 5%... Union Pacific (UNP), up 3%... Blackstone (BX), up 2.5%... Novartis (NVS), up 5%. ALSO HIGHER: Inseego (INSG), up 7% after Verizon (VZ) debuted its fifth 5G-enabled device with the launch of the company's MiFi M1000. DOWN AFTER EARNINGS: Netflix (NFLX), down 11%... Morgan Stanley (MS), down 1.5%... SAP (SAP), down 6%... IBM (IBM), down 1%. ALSO LOWER: Forty Seven (FTSV), down 3% after its 9.38M share secondary priced at $8.00 per share... Amarin (AMRN), down 8% after announcing that it has commenced an underwritten public offering of $400M of its American depositary shares.

NFLX

Netflix

$362.50

-3.22 (-0.88%)

EBAY

eBay

$39.03

-0.87 (-2.18%)

PM

Philip Morris

$81.06

-0.49 (-0.60%)

MS

Morgan Stanley

$43.78

-0.63 (-1.42%)

IBM

IBM

$143.07

-0.47 (-0.33%)

INSG

Inseego

$5.03

-0.13 (-2.52%)

VZ

Verizon

$57.22

-0.18 (-0.31%)

UNP

Union Pacific

$164.05

-11.05 (-6.31%)

BX

Blackstone

$45.27

-0.555 (-1.21%)

NVS

Novartis

$90.11

0.99 (1.11%)

BBT

BB&T

$49.68

0.04 (0.08%)

SAP

SAP

$134.22

-0.9 (-0.67%)

FTSV

Forty Seven

$8.77

-1.38 (-13.60%)

AMRN

Amarin

$21.06

-0.68 (-3.13%)

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 22

    Jul

  • 23

    Jul

  • 24

    Jul

  • 01

    Aug

  • 01

    Aug

  • 08

    Aug

  • 26

    Aug

  • 04

    Sep

  • 05

    Sep

  • 06

    Sep

  • 09

    Sep

  • 11

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 18

    Jul

  • 19

    Jul

NFLX Netflix
$362.50

-3.22 (-0.88%)

07/18/19
MSCO
07/18/19
NO CHANGE
Target $450
MSCO
Overweight
Morgan Stanley offers reasons 'not to overreact' to Netflix subscriber miss
Morgan Stanley analyst Benjamin Swinburne offered several "arguments not to overreact" to Netflix's Q2 subscriber miss, beginning by noting that the company has missed its quarterly net additions forecast once a year in each of the last three years. In all three of these cases, the company has outperformed meaningfully the following quarter, he pointed out and in two cases the miss came in the seasonally light second quarter. Additionally, the magnitude of this miss relative to the size of the business is similar to prior misses, said Swinburne, who contends that Netflix's ability to forecast has not meaningfully changed. The analyst, whose full year net additions, revenue and earnings estimates are largely unchanged following last night's report, keeps an Overweight rating and $450 price target on Netflix shares.
07/18/19
ADAM
07/18/19
NO CHANGE
Target $415
ADAM
Buy
Netflix subscriber weakness likely temporary, says Canaccord
Canaccord analyst Michael Graham noted Netflix reported mixed results as the subscriber net additions missed guidance and his estimates, but revenue growth accelerated for the second straight quarter, and Q3 subscriber growth should accelerate on international strength. The analyst said the subscriber miss may weigh on the shares but he still sees a strong content strategy and room to add large numbers of international subscriptions going forward. Graham reiterated his Buy rating and $415 price target on Netflix shares.
07/18/19
OPCO
07/18/19
NO CHANGE
Target $410
OPCO
Outperform
Netflix early Q3 shows 'rebound,' says Oppenheimer
Oppenheimer analyst Jason Helfstein reiterates an Outperform rating and a $410 price target on Netflix's shares despite weaker than expected subscriber growth. The analyst notes that Q3 global net add guidance is 11% above the Street, on stronger content releases, which should offset Q2 concerns. Additionally, fiscal year margin outlook is unchanged, and free cash flow losses are expected to moderate in 2020, he contends. Overall, Helfstein still sees Netflix on track to garner material growth in global broadband homes.
07/18/19
WBLR
07/18/19
NO CHANGE
WBLR
Outperform
Netflix fundamentals unchanged after Q2 subscriber miss, says William Blair
In three of the last four second quarters, including last night, Netflix has missed subscriber guidance, William Blair analyst Ralph Schackart tells investors in a research note. In 2016 and 2018, misses in Q2 were both followed by "strong beats" to the tune of 1M subscribers in Q3, added the analyst. Further, he notes that management said Q3 of 2019 was off to a strong start in terms of subscriber additions, attributable to Stranger Things. Schackart believes Netflix's fundamentals have not changed as the company "continues its march into streamed TV." From here, the analyst sees roughly 18% share upside over the next 12 months using a long-term earnings valuation framework, which models compounded earnings growth of 34% through 2025 and a multiple of 26 times forward earnings. He forecasts 298M global subscribers at year-end 2025, and a stock price of roughly a $621 stock by 2024, with a discounted value today of roughly $378. Schackart keeps an Outperform rating on Netflix shares.
EBAY eBay
$39.03

-0.87 (-2.18%)

07/18/19
DADA
07/18/19
NO CHANGE
Target $47
DADA
Buy
eBay price target raised to $47 from $44 at DA Davidson
DA Davidson analyst Tom Forte raised his price target on eBay (EBAY) to $47 and kept his Buy rating after its above-consensus results in Q2, saying the activist investor involvement in the company is bringing out its "best" with "strong" operating metrics, margin expansion, and an "aggressive" buyback. The analyst adds that he found the company's answers about the implications of Facebook's (FB) Libra cryptocurrency efforts encouraging in its potential to reduce the transaction costs on eBay's platform.
07/18/19
FBCO
07/18/19
NO CHANGE
Target $49
FBCO
Outperform
eBay price target raised to $49 from $43 at Credit Suisse
Credit Suisse analyst Stephen Ju raised his price target for eBay to $49 from $43 following quarterly results. The analyst reiterates an Outperform rating on the shares.
07/18/19
BNCH
07/18/19
NO CHANGE
Target $50
BNCH
Buy
eBay price target raised to $50 from $45 at Benchmark
Benchmark analyst Daniel Kurnos said eBay reported "another quarter of underwhelming" gross merchandise volume, but the magnitude of the tailwind from promoted listings and intermediated payments drove a slight revenue beat and allowed management to maintain its organic, currency neutral revenue growth guidance. The analyst, who raised his price target on eBay shares to $50 from $45 following the earnings report, noted that his valuation does not factor in any asset sales, which he estimates could represent upwards of $10 per share in added value. Kurnos keeps a Buy rating on eBay shares.
07/18/19
DBAB
07/18/19
NO CHANGE
Target $46
DBAB
Buy
eBay price target raised to $46 from $42 at Deutsche Bank
Deutsche Bank analyst Lloyd Walmsley raised his price target for eBay to $46 from $42 citing last night's "strong" Q2 results. Although gross merchandise volume was was flat year-over-year excluding currency, which was largely anticipated based on third party data, revenue was up 4%, modestly above the Street on continued growth in Promoted Listings, Walmsley tells investors in a research note. He maintains a Buy rating on eBay shares.
PM Philip Morris
$81.06

-0.49 (-0.60%)

06/19/19
WELS
06/19/19
NO CHANGE
Target $100
WELS
Outperform
Philip Morris recent selloff 'unjustified,' says Wells Fargo
Wells Fargo analyst Bonnie Herzog reiterates her bullish call on Philip Morris and believes the recent selloff in the stock is "unjustified." The analyst sees this as an opportunity for long-term investors to enter or build positions in what she believes is one of the "most attractive CPG stocks" in terms of growth prospects and yield characteristics. Herzog reiterates an Outperform rating and $100 price target on the shares.
07/16/19
WELS
07/16/19
NO CHANGE
WELS
Wells says Nielsen restatement could be positive for Monster, tobacco stocks
Wells Fargo analyst Bonnie Herzog noted that Nielsen (NLSN) just announced that it will restate data to address serious issues with its calculation methodology in the convenience store channel related to projections it applied to independent c-stores. The restated data, to be released on August 20, is expected to improve cigarette and energy drink trends and she views this as a positive for tobacco stocks and Monster Beverage (MNST). Publicly traded companies in the tobacco space include Altria Group (MO), British American Tobacco (BTI) and Philip Morris (PM).
05/28/19
SBSH
05/28/19
NO CHANGE
SBSH
Cigarette data from Nielsen 'dire,' industry data also 'very bad,' says Citi
Citi analyst Adam Spielman noted that Nielsen reported earlier today that cigarette industry volumes fell 11.2% in the four weeks ended May 18, noting that shares of Altria (MO), British American Tobacco (BTI) and Imperial (IMBBY) all fell following the "dire" data. Volumes in MSAi, the industry database that he regards as much more reliable than Nielsen, were down 6.4% in the same period, which Spielman said "is still a very bad figure, but it is a lot, lot better than the Nielsen one." Looking ahead, the analyst said he expects "gradually less bad" volumes in Nielsen in the rest of the year, though he noted that Altria has said it expects industry volumes to fall about 4%-5% this year and he forecasts a decline of about 6%. In late afternoon trading, Altria shares are down 4.5%, British American has declined over 4% and Philip Morris (PM) is down 5%.
07/01/19
PIPR
07/01/19
NO CHANGE
Target $100
PIPR
Overweight
Philip Morris checks in Japan show iQOS momentum, says Piper Jaffray
Piper Jaffray analyst Michael Lavery says his recent channel checks in Japan suggest "good momentum" for iQOS. The analyst continues to believe iQOS is the most compelling heated tobacco product and he maintains an Overweight rating on Philip Morris shares with a $100 price target.
MS Morgan Stanley
$43.78

-0.63 (-1.42%)

07/12/19
SBSH
07/12/19
UPGRADE
SBSH
Buy
Morgan Stanley upgraded to Buy from Neutral at Citi
Citi analyst Keith Horowitz upgraded Morgan Stanley to Buy from Neutral.
07/17/19
BMOC
07/17/19
NO CHANGE
Target $273
BMOC
Market Perform
Goldman Sachs price target raised to $273 from $260 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on Goldman Sachs (GS) to $273 after its "equities-driven" beat on the top line in Q2 and rolled out valuation. The analyst maintains his Market Perform rating however, saying he continues to prefer Morgan Stanley (MS) to Goldman Sachs given the lower valuation of the former and continued risks around the 1MDB issues of the latter.
07/12/19
07/12/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Altria Group (MO) upgraded to Buy from Neutral at Goldman Sachs with analyst Judy Hong saying the valuations in the tobacco sector are trading at a 10-year trough in spite of the "more accommodating" macro backdrop for Consumer Staples that includes a late cycle and lower yields. 2. Focus Financial (FOCS) upgraded to Outperform from Market Perform at Keefe Bruyette. 3. Deutsche Bank (DB) upgraded to Neutral from Sell at UBS. 4. Morgan Stanley (MS) upgraded to Buy from Neutral at Citi. 5. Snap (SNAP) upgraded to Buy from Neutral at Goldman Sachs with analyst Heath Terry saying the company's new Android app, the launch of Snap Games, and new viral lenses should accelerator user growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/19
SBSH
07/12/19
NO CHANGE
SBSH
Morgan Stanley upgrade, Wells downgrade among Citi's bank changes
Citi analyst Keith Horowitz made seven rating changes in the U.S. Banks space after updating his estimates and target prices for a new base case rate forecast that more closely reflects the forward curve. This includes two interest rate cuts in 2019 and 2020. The analyst's terminal yield curve assumptions to Fed Funds is 1.75%. The lower rate assumptions led him to lower his normal return on tangible equity estimates ~100 basis points on average. Following these changes, Horowitz upgraded Morgan Stanley (MS) to Buy from Neutral), downgraded Comerica (CMA), Northern Trust (NTRS), and M&T Bank (MTB) to Sell from Neutral, and downgraded Wells Fargo (WFC), Citizens Financial (CFG), and Fifth Third (FITB) to Neutral from Buy.
IBM IBM
$143.07

-0.47 (-0.33%)

07/18/19
NOMU
07/18/19
NO CHANGE
Target $165
NOMU
Buy
IBM price target raised to $165 from $160 at Nomura Instinet
Nomura Instinet analyst Jeffrey Kvaal raised his price target for IBM to $165 from $160 saying sales upside in the highest margin segments and a "solid" earnings beat in Q2 lifted visibility into the company's full-year guidance. The analyst keeps a Buy rating on IBM shares.
07/09/19
STFL
07/09/19
NO CHANGE
Target $169
STFL
Buy
Red Hat closing probably earlier than most expected, says Stifel
Stifel analyst David Grossman said IBM's (IBM) closing of its Red Hat (RHT) acquisition probably came earlier than most expected, adding that IBM will report standalone Q2 results next week, on July 17, and than will provide an update including Red Hat on a webcast scheduled for August 2. IBM is set up as a defensive holding with two potential catalysts, namely continued improvement in its core infrastructure services business and demonstrated success in leveraging Red Hat, said Grossman, who keeps a Buy rating and $169 price target on IBM shares.
07/18/19
MSCO
07/18/19
NO CHANGE
MSCO
IBM showing growth 'in all the right places,' says Morgan Stanley
Morgan Stanley analyst Katy Huberty noted that IBM's Q2 revenue was "just in-line," but she said the company is showing growth in "all the right places" as the segments aligning with its strategy of helping customers digitally transform to cloud and cognitive enterprises were strong. Cloud & Data Software constant currency revenue growth accelerated to 5% and Global Business Services delivered revenue and margin expansion for another quarter, noted Huberty. The analyst, who added that she thinks the company's tone on the earnings conference call "seemed bullish," does not have a rating on IBM shares.
07/18/19
JPMS
07/18/19
INITIATION
Target $147
JPMS
Neutral
IBM reinstated with a Neutral at JPMorgan
JPMorgan analyst Tien-tsin Huang reinstated coverage of IBM with a Neutral rating and $147 price target following a period of restriction. The rating is unchanged while the price target is reduced from $160. The analyst, who views last night's Q2 results as "fine," says he lacks conviction on near-term stock upside potential from the Red Hat deal.
INSG Inseego
$5.03

-0.13 (-2.52%)

05/24/19
COWN
05/24/19
INITIATION
Target $8
COWN
Outperform
Inseego initiated with an Outperform, $8 target at Cowen
Cowen analyst Lance Vitanza started Inseego with an Outperform rating and $8 price target. The company has a strong position within the "burgeoning" 5G market, Vitanza tells investors in a research note. With an estimated 20% annual revenue growth over the next few years, the stock deserves a premium valuation, says the analyst. He sees a "multitude of multi-billion-dollar market segments" to which Inseego technology can serve.
03/20/19
NATL
03/20/19
INITIATION
Target $6
NATL
Buy
Inseego initiated with a Buy at National Securities
National Securities analyst Matthew Galinko initiated Inseego (INSG) with a Buy rating and $6 price target, citing his view that its fundamentals, from product execution to go-to-market, are improving and that its recent wins with other carriers should help its concentration with Verizon (VZ) become less severe.
05/24/19
05/24/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zoom Video (ZM) initiated with a Perform at Oppenheimer. 2. CannTrust (CTST) initiated with a Buy at BofA/Merrill. 3. Inseego (INSG) initiated with an Outperform at Cowen. 4. Falcon Minerals (FLMN) initiated with an Outperform at Baird. 5. Aphria (APHA) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/24/19
COWN
05/24/19
INITIATION
COWN
Outperform
Inseego initiated with an Outperform at Cowen
VZ Verizon
$57.22

-0.18 (-0.31%)

07/08/19
07/08/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Sell from Neutral at Rosenblatt with analyst Jun Zhang citing his view that its fundamental will deteriorate over the next 6-12 months. 2. Verizon (VZ) downgraded to Neutral from Buy at Citi with analyst Michael Rollins saying rising long-term industry risks and the stock's current valuation premium are likely to limit returns over the next 12-months. 3. F5 Networks (FFIV) downgraded to Sell from Neutral at Goldman Sachs with analyst Rod Hall saying the company's earnings risks are increasing due to the weaker short-term spending environment and increasing competitive threat. 4. BNY Mellon (BK) and State Street (STT) were double downgraded to Underweight from Overweight at Morgan Stanley. 5. American Airlines (AAL) downgraded to Underperform from Neutral at Credit Suisse with analyst Jose Caiado citing labor and Boeing (BA) 737 Max risk. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/08/19
SBSH
07/08/19
DOWNGRADE
Target $62
SBSH
Neutral
Citi downgrades Verizon to Neutral on rising long-term industry risks
Citi analyst Michael Rollins downgraded Verizon Communications (VZ) to Neutral from Buy with an unchanged price target of $62. Rising long-term industry risks and the stock's current valuation premium are likely to limit returns over the next 12-months, Rollins tells investors in a research note. He believes long-term risks are rising for industry pricing and margins given the "widening array of possible outcomes" for the proposed merger of T-Mobile (TMUS) and Sprint (S). Rollins thinks national wireless firms that take more aggressive steps to shape their long-term strategic and competitive position in the industry have a better chance of creating value over the next 12-months. As such, he maintains Buy ratings on T-Mobile, AT&T (T), Telephone and Data (TDS) and U.S. Cellular (USM).
07/08/19
SBSH
07/08/19
DOWNGRADE
Target $62
SBSH
Neutral
Verizon downgraded to Neutral from Buy at Citi
Citi analyst Michael Rollins downgraded Verizon Communications to Neutral from Buy with a $62 price target.
07/11/19
FBCO
07/11/19
NO CHANGE
Target $556
FBCO
Outperform
Equinix price target raised to $556 from $506 at Credit Suisse
Credit Suisse analyst Sami Bad raised his price target for Equinix (EQIX) to $556 from $506, citing his firm's CIO July 2019 Survey indicating further strength for colocation vendors, a 5G interconnection inflection projected as early as Q4, leading to an acceleration of interconnectivity growth, and organic growth continuing to accelerate as the company laps its recent acquisitions including Verizon (VZ) data centers, Itconic, Zenium-Istanbul, Metronode Australia, and Infomart Dallas. The analyst reiterates an Outperform rating on Equinix's shares.
UNP Union Pacific
$164.05

-11.05 (-6.31%)

06/17/19
06/17/19
DOWNGRADE
Target $177

Market Perform
Union Pacific downgraded to Market Perform at Bernstein
As previously reported, Bernstein analyst David Vernon downgraded Union Pacific to Market Perform from Outperform and lowered its price target on the shares to $177 from $190. The analyst believes is not worth playing in a down freight market as rail stocks do not work in a down truck market.
07/17/19
CKCP
07/17/19
DOWNGRADE
CKCP
Union Pacific downgraded to Hold from Buy at Cascend Securities
07/17/19
CSND
07/17/19
DOWNGRADE
CSND
Hold
Cascend downgrades four rails on weakening intermodal traffic
Cascend Securities downgraded four names in the rail space, CSX (CSX), Norfolk Southern (NSC), Kansas City Southern (KSU), and Union Pacific (UNP), to Hold after three years at Buy. Intermodal traffic is down since February, and it doesn't look like a "pause," Cascend tells investors in a research note. Further, industrial equipment imports into the U.S. has suddenly declined sharply, adds the firm, which notes that CSX last night called the economic backdrop "puzzling."
07/10/19
GSCO
07/10/19
INITIATION
Target $198
GSCO
Buy
Union Pacific initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Jordan Alliger started Union Pacific with a Buy rating and $198 price target. The analyst thinks shares of Union Pacific still offer upside in the context of its recent implementation of PSR. The company should generate near the high end of rail operating rail improvement in 2019-2021, Alliger tells investors in a research note.
BX Blackstone
$45.27

-0.555 (-1.21%)

06/27/19
SBSH
06/27/19
NO CHANGE
SBSH
Blackstone removed from U.S. Focus List at Citi
Citi analyst William Katz removed Blackstone (BX) from his firm's U.S. Focus List following the stock's 40% year-to-date appreciation. The analyst sees greater upside elsewhere but believes Blackstone's fundraising and business diversification "remains best-in-class." value. Apollo Global (APO) now sits atop the analyst's ranks given the company's "incrementally more attractive risk/reward paired with favorable C-Corp catalysts."
07/08/19
JMPS
07/08/19
DOWNGRADE
JMPS
Market Perform
Blackstone downgraded to Market Perform from Outperform at JMP Securities
JMP Securities analyst Devin Ryan downgraded Blackstone to Market Perform from Outperform, stating that his conversations with investors lead him to believe that many generalist money managers have been underweight Financials for some time and that this accelerated when the yield curve inverted earlier in the year. While he remains bullish on fundamentals, Ryan thinks the risk/reward in some of the more recent outperformers, such as Blackstone, is becoming more balanced, he said.
07/15/19
BOFA
07/15/19
INITIATION
Target $70
BOFA
Neutral
Thomson Reuters reinstated with a Neutral at BofA/Merrill
BofA Merrill Lynch analyst Gary Bisbee reinstated coverage of Thomson Reuters (TRI) with a Neutral rating and $70 price target, telling investors that the company's sale of a 55% stake in Refinitiv to Blackstone (BX) is a win-win and that the "new" Thomson is a "cleaner, faster growth story." However, he also sees this being largely priced in after a run-up in the stock over the last twelve months.
07/09/19
MSCO
07/09/19
NO CHANGE
MSCO
Morgan Stanley sees C-corp conversion announcement coming from Carlyle
Morgan Stanley analyst Michael Cyprys said he recommends owning Carlyle Group (CG) shares into the quarter, as he believes the company will announce plans to convert to a C-corporation along with its upcoming report, "albeit with a delayed effective date" to allow time for the complex underlying tax impact analysis. He thinks a conversion could bring greater clarity and visibility into targets, which could increase long only interest in the stock, Cyprys tells investors. In his broader preview of the earnings season for the Asset Manager group, the analyst noted that he lowered his Q2 EPS estimates by about 4% on average, cutting his estimates for Traditionals by 0.5%, for Alts by 11.5% and for Market Structure companies by 1.6%.
NVS Novartis
$90.11

0.99 (1.11%)

06/28/19
PIPR
06/28/19
DOWNGRADE
Target $250
PIPR
Neutral
Biogen downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond downgraded Biogen (BIIB) to Neutral from Overweight and lowered his price target for the shares to $250 from $280. The stock closed yesterday up $1.70 to $239.77. Piper's new neurologist survey data from Spherix Global Insights "spells bad news for both Tecfidera and Tysabri in the near and longer term," Raymond tells investors in a research note. For the first time in a long time, Tecfidera market share is projected to contract over the next six months, primarily at the hands of Novartis' (NVS) new entrant Mayzent, explains the analyst. Further, Raymond notes that while prior surveys have indicated a plateauing of Roche's (RHHBY) Ocrevus with Biogen's Tysabri "hanging in there," the most recent indications are for an accelerating Ocrevus with Tysabri the "clear loser." The analyst lowered his estimates for both Tecfidera and Tysabri and downgraded Biogen.
06/18/19
06/18/19
DOWNGRADE

Hold
Regeneron downgraded to Hold at Argus on mounting threats to Eylea
As previously reported, Argus analyst Jasper Hellweg downgraded Regeneron (REGN) to Hold from Buy, saying that while the company has a "strong pipeline" with new recent indications for multiple products, its primary revenue driver Eylea is facing several competitive threats. The analyst notes that Novartis (NVS) could launch a biologic designed to treat Eylea's key indication of wet age-related macular degeneration by the end of Q2 and also notes that the drug's patents are set to expire in 2022 in China and Japan, 2023 in the U.S., and 2024 in Europe. Hellweg adds that he will return his Regeneron rating to Buy if the company demonstrates that it can offset the impact of reduced Eylea sales, which accounted for over 75% of total revenue in Q1.
07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/17/19
RAJA
07/17/19
NO CHANGE
RAJA
Investors shouldn't overreact to drug proposal headlines, says Raymond James
Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
BBT BB&T
$49.68

0.04 (0.08%)

03/26/19
03/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bed Bath & Beyond (BBBY) upgraded to Strong Buy from Market Perform at Raymond James , to Hold from Sell at Loop Capital, and to Sector Weight from Underweight at KeyBanc. 2. BB&T (BBT) upgraded to Buy from Hold at Deutsche Bank with analyst Matt O'Connor saying after meeting with CEO of SunTrust (STI), he remains positive on the merger and the combined stock. 3. Vertex (VRTX) upgraded to Outperform from Market Perform at William Blair with analyst Y. Katherine Xu citing expectations that the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. 4. Allegiant Travel (ALGT) upgraded to Outperform from Neutral at Macquarie with analyst Susan Donofrio citing her meetings with its management last week. 5. TransAlta (TAC) upgraded to Buy from Hold at TD Securities with analyst John Mould saying Brookfield Renewable Partners (BEP) $750M investment in TransAlta improves the company's financial flexibility, accelerates its ability to return capital to shareholders and advance the coal-to-gas conversion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/04/19
04/04/19
UPGRADE
Target $44

Strong Buy
Synovus upgraded to Strong Buy at Raymond James
As previously reported, Raymond James analyst David Lon upgraded Synovus (SNV) to Strong Buy from Outperform, with a $44 price target. The analyst cited the recent pullback in the stock and what he sees as an outsized opportunity for market share gain stemming from the recently announced BB&T (BBT)-SunTrust (STI) mega merger.
04/04/19
RAJA
04/04/19
DOWNGRADE
RAJA
Market Perform
BB&T downgraded to Market Perform from Outperform at Raymond James
04/04/19
RAJA
04/04/19
DOWNGRADE
RAJA
Market Perform
BB&T downgraded to Market Perform on near-term noise at Raymond James
As previously reported, Raymond James analyst David Lon downgraded BB&T (BBT) to Market Perform from Outperform and reducing his EPS estimates. The analyst cited the nearer-term noise surrounding its merger with SunTrust (STI) and his view that BB&T shares are unlikely to outperform until there is greater clarity on when the deal will actually close and its ability to retain key talent with the combined company's footprint. Moreover, larger acquirer stock prices generally haven't reacted favorably over the past few years, he contends.
SAP SAP
$134.22

-0.9 (-0.67%)

06/17/19
HSBC
06/17/19
UPGRADE
HSBC
Buy
SAP upgraded to Buy from Hold at HSBC
HSBC analyst Antonin Baudry upgraded SAP to Buy from Hold and raised his price target for the shares to 135 euros from 110 euros. The analyst believes the company is "unlocking potential" for margin expansion.
04/25/19
RBCM
04/25/19
NO CHANGE
Target $133
RBCM
Sector Perform
SAP price target raised to $133 from $115 at RBC Capital
RBC Capital analyst Ross MacMillan raised his price target on SAP to $133 after its better than expected Q1 results, with upside highlighted by the company's Cloud gross margins. The analyst also points to the management's plan targeting higher margins and profit growth. MacMillan keeps his Sector Perform rating on SAP but says he is more positive on the stock after this quarter, looking to do "more work" on the company's upside potential.
04/29/19
04/29/19
UPGRADE
Target $167

Outperform
SAP upgraded to Outperform at RBC Capital on better profitability path
As previously reported, RBC Capital analyst Ross MacMillan upgraded SAP to Outperform and raised his price target to $167 from $133. The analyst believes that the company's future earnings growth could come from strong cloud business performance and improved capital allocation. MacMillan also cites SAP management's commitment to expanding operating margins as well as the company's "stable" core business, adding that the valuation on the shares is "relatively attractive."
04/29/19
RBCM
04/29/19
UPGRADE
Target $167
RBCM
Outperform
SAP upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital analyst Ross Macmillan upgraded SAP to Outperform from Sector Perform and raised his price target for the shares to $167 from $133.
FTSV Forty Seven
$8.77

-1.38 (-13.60%)

02/01/19
JONE
02/01/19
INITIATION
Target $30
JONE
Buy
Forty Seven initiated with a Buy at JonesTrading
JonesTrading analyst Soumit Roy initiated Forty Seven with a Buy rating and $30 price target, stating that following the success of anti-PD(L)-1 drugs targeting T cells, macrophages are a target to get reengaged in the fight against cancer. Forty Seven's anti-CD47 antibody, 5F9, is clinically the most advanced and "at least 12-18 months ahead of peers," Roy tells investors.
05/28/19
ROTH
05/28/19
INITIATION
Target $28
ROTH
Buy
Roth Capital starts Forty Seven with Buy rating ahead of 2019 catalysts
Roth Capital analyst Tony Butler initiated coverage of Forty Seven with a Buy rating and $28 price target. The company has multiple data driven catalysts for 2019, with a focus on non-Hodgkin's lymphoma, Butler tells investors in a research note. He anticipates "promising efficacy" results in the higher dose cohort. Further, new clinical partnerships for combo therapies with Genentechand Acerta could allow for shared development costs and support increased efficacy and earlier line use of Forty Seven's lead antibody 5F9, says Butler.
04/12/19
GUGG
04/12/19
INITIATION
Target $25
GUGG
Buy
Forty Seven initiated with a Buy at Guggenheim
Guggenheim analyst Michael Schmidt started Forty Seven with a Buy rating and $25 price target. The company is the scientific and clinical leader in targeting CD47, a novel mechanistic approach with "significant" market potential if successful, Schmidt tells investors in a research note. The analyst believes multiple early clinical-phase data readouts through 2019 may establish proof-of-concept in additional tumor types.
05/28/19
ROTH
05/28/19
INITIATION
Target $28
ROTH
Buy
Forty Seven initiated with a Buy at Roth Capital
Roth Capital analyst Tony Butler started Forty Seven with a Buy rating and $28 price target.
AMRN Amarin
$21.06

-0.68 (-3.13%)

07/18/19
07/18/19
INITIATION
Target $7

Outperform
Oppenheimer bullish on Acasti Pharma, initiates with an Outperform
As previously reported, Oppenheimer analyst Leland Gershell started coverage of Acasti Pharma (ACST) with an Outperform rating and $7 price target. While the analyst notes that Vascepa's prospects to serve a multibillion-dollar sales opportunity have driven significant value appreciation for Amarin (AMRN), he believes Acasti Pharma's potentially best-in-class omega-3 is only months away from pivotal readouts in the very high triglycerides niche, and anticipates a REDUCE-IT-like label expansion can be secured without new outcomes data. With shares trading at just a about $100M EV, Gershell believes Acasti holds "considerable upside" as CaPre approaches commercialization, its advantages are better appreciated, and Vascepa's sales growth continues to impress.
07/03/19
ROTH
07/03/19
NO CHANGE
Target $31
ROTH
Buy
Amarin 'just getting started' as Vascepa sales sets new high, says Roth Capital
Roth Capital analyst Yasmeen Rahimi notes that Amarin provided record revenue for the first half of 2019 for Vascepa, guided $380M-420M for 2019 and unveiled its plans to increase its U.S. sales team to about 800 in October 2019. The analyst believes the company's power move is just the beginning of transformation into a money maker, while noting that there is still no word on AdCom as PDUFA approaches. Rahimi reiterates a Buy rating and $31 price target on the shares.
07/09/19
JEFF
07/09/19
NO CHANGE
JEFF
Buy
Amarin weakness may be due to hiring worries, Citizen's Petition, says Jefferies
Jefferies analyst Michael Yee noted that Amarin shares have been weak today and he said that investors he has spoke with have discussed the company's plans to double its salesforce near-term, which would increase operating expenses and the use of cash. Yee said he is also aware that there was a Citizen's Petition filed today by a group seeking to invalidate the company's '146 manufacturing patent, challenging the concept of producing pure EPA from crude fish oil. However, he said that a Citizen Petitions to invalidate a patent would seem challenging, as he thinks the more appropriate medium would be a formal court process or an IPR challenge. The petition "sounds noisy," added Yee, who has a Buy rating on Amarin shares.
07/09/19
AGIS
07/09/19
INITIATION
Target $3
AGIS
Buy
Aegis starts 'promising Omega-3 story' Acasti with Buy rating, $3 price target
As previously reported, Aegis analyst Nathan Weinstein initiated Acasti Pharma (ACST) with a Buy rating and $3 price target, telling investors that the company's Omega-3 therapeutic for the treatment of very high triglycerides, called CaPre, has demonstrated "interesting efficacy" in phase 2 study. Several companies have entered or could be close to entering the prescription Omega-3 space, including Amarin (AMRN), but Weinstein points to precedent cases of third and later entrants achieving market success in various therapeutic categories.

TODAY'S FREE FLY STORIES

CBS

CBS

$43.83

0.5 (1.15%)

, VIA

Viacom

$27.27

-0.4 (-1.45%)

08:03
08/17/19
08/17
08:03
08/17/19
08:03
Periodicals
Viacom-CBS merger got panned by investors, Barron's says »

CBS (CBS) and Viacom…

CBS

CBS

$43.83

0.5 (1.15%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

VIAB

Viacom

$26.02

0.09 (0.35%)

AAPL

Apple

$206.44

4.71 (2.33%)

DIS

Disney

$135.19

1.79 (1.34%)

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

NFLX

Netflix

$302.74

6.81 (2.30%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

  • 27

    Oct

MYGN

Myriad Genetics

$25.36

2.14 (9.22%)

07:57
08/17/19
08/17
07:57
08/17/19
07:57
Periodicals
Myriad Genetics stock might have an FDA issue, Barron's says »

Myriad Genetics plunged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CSCO

Cisco

$46.96

0.73 (1.58%)

, NTAP

NetApp

$46.75

0.33 (0.71%)

07:50
08/17/19
08/17
07:50
08/17/19
07:50
Periodicals
Trade war hitting tech stocks, Barron's says »

Cisco (CSCO) plunged 9% a…

CSCO

Cisco

$46.96

0.73 (1.58%)

NTAP

NetApp

$46.75

0.33 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

  • 10

    Oct

  • 13

    Nov

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

, RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

07:47
08/17/19
08/17
07:47
08/17/19
07:47
Periodicals
Investors should not abandon oil, gas stocks, Barron's says »

Energy stocks have rarely…

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

BP

BP

$36.27

0.22 (0.61%)

XOM

Exxon Mobil

$68.30

1.06 (1.58%)

CVX

Chevron

$115.79

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 25

    Sep

TGT

Target

$84.20

1.67 (2.02%)

, WMT

Walmart

$112.99

0.32 (0.28%)

07:40
08/17/19
08/17
07:40
08/17/19
07:40
Periodicals
Grocery Outlet thriving as rivals struggle, Barron's says »

While Dow was down 800…

TGT

Target

$84.20

1.67 (2.02%)

WMT

Walmart

$112.99

0.32 (0.28%)

GO

Grocery Outlet

$46.55

2.81 (6.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

AEO

American Eagle

$15.40

0.63 (4.27%)

07:33
08/17/19
08/17
07:33
08/17/19
07:33
Periodicals
American Eagle to soar despite trade war, Barron's says »

American Eagle's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 25

    Sep

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

, MTCH

Match Group

$84.53

2.08 (2.52%)

07:27
08/17/19
08/17
07:27
08/17/19
07:27
Periodicals
Dating business might be IAC's best asset, greatest challenge, Barron's says »

IAC (IAC) has rallied 34%…

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

MTCH

Match Group

$84.53

2.08 (2.52%)

IAC

IAC

$249.17

4.21 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 10

    Sep

  • 10

    Oct

AAPL

Apple

$206.44

4.71 (2.33%)

, HAS

Hasbro

$114.29

1.13 (1.00%)

07:13
08/17/19
08/17
07:13
08/17/19
07:13
On The Fly
Week in review How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$206.44

4.71 (2.33%)

HAS

Hasbro

$114.29

1.13 (1.00%)

MAT

Mattel

$10.74

(0.00%)

AGR

Avangrid

$49.29

0.37 (0.76%)

JPM

JPMorgan

$107.73

2.52 (2.40%)

BAC

Bank of America

$27.04

0.79 (3.01%)

C

Citi

$63.46

2.13 (3.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 09

    Sep

  • 02

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 27

    Oct

NCLH

Norwegian Cruise Line

$50.48

1.38 (2.81%)

18:04
08/16/19
08/16
18:04
08/16/19
18:04
Hot Stocks
Norwegian Cruise Line CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RM

Regional Management

$27.12

0.14 (0.52%)

18:01
08/16/19
08/16
18:01
08/16/19
18:01
Hot Stocks
Regional Management CFO buys 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

RTN

Raytheon

$178.10

-0.42 (-0.24%)

17:59
08/16/19
08/16
17:59
08/16/19
17:59
Hot Stocks
Raytheon awarded $199.59M Navy contract for MK 15 CIWS »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$19.94

0.16 (0.81%)

17:57
08/16/19
08/16
17:57
08/16/19
17:57
Hot Stocks
Breaking Hot Stocks news story on Wendy's »

Trian Fund lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BRY

Berry Petroleum

$8.59

0.39 (4.76%)

17:54
08/16/19
08/16
17:54
08/16/19
17:54
Syndicate
Breaking Syndicate news story on Berry Petroleum »

Berry Petroleum files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSWI

CSW Industrials

$70.20

1.92 (2.81%)

17:52
08/16/19
08/16
17:52
08/16/19
17:52
Hot Stocks
CSW Industrials CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAS

Oasis Petroleum

$3.03

0.135 (4.66%)

17:49
08/16/19
08/16
17:49
08/16/19
17:49
Hot Stocks
Oasis Petroleum CEO buys 30K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EE

El Paso Electric

$66.41

0.005 (0.01%)

17:45
08/16/19
08/16
17:45
08/16/19
17:45
Hot Stocks
El Paso Electric director Wertheimer sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HON

Honeywell

$165.07

2.81 (1.73%)

17:42
08/16/19
08/16
17:42
08/16/19
17:42
Hot Stocks
Honeywell CEO sells 7.1K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBRX

Moleculin Biotech

$1.08

0.01 (0.93%)

17:37
08/16/19
08/16
17:37
08/16/19
17:37
Earnings
Moleculin Biotech reports Q2 EPS (3c), two estimates (10c) »

CFO Jonathan Foster…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIVE

Viveve

$0.13

0.0046 (3.59%)

17:35
08/16/19
08/16
17:35
08/16/19
17:35
Syndicate
Breaking Syndicate news story on Viveve »

Viveve files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRGO

Perrigo

$46.21

0.535 (1.17%)

17:30
08/16/19
08/16
17:30
08/16/19
17:30
Hot Stocks
Breaking Hot Stocks news story on Perrigo »

Starboard lowers Perrigo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

UAL

United Continental

$82.96

1.36 (1.67%)

17:28
08/16/19
08/16
17:28
08/16/19
17:28
Hot Stocks
United Continental director Shapiro buys 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 05

    Sep

  • 23

    Sep

MBIO

Mustang Bio

$3.88

0.19 (5.15%)

17:26
08/16/19
08/16
17:26
08/16/19
17:26
Syndicate
Breaking Syndicate news story on Mustang Bio »

Mustang Bio files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

BCLI

BrainStorm

$3.63

0.055 (1.54%)

17:24
08/16/19
08/16
17:24
08/16/19
17:24
Syndicate
Breaking Syndicate news story on BrainStorm »

BrainStorm files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLK

Westlake Chemical

$61.27

0.66 (1.09%)

17:15
08/16/19
08/16
17:15
08/16/19
17:15
Hot Stocks
Westlake Chemical raises quarterly dividend by 5% to 26.25c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIG

GigCapital

$10.30

(0.00%)

17:10
08/16/19
08/16
17:10
08/16/19
17:10
Hot Stocks
GigCapital receives noncompliance notice from NYSE »

GigCapital announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.